# IMAC Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/IMAC Holdings, Inc.). ## Overview IMAC Holdings, Inc. is a U.S.-based specialty healthcare and life sciences company that now operates primarily through Ignite Proteomics, LLC. Ignite uses a patented RPPA proteomics platform to measure protein signaling and support oncology treatment decisions and biopharmaceutical drug development, while the legacy IMAC clinical operations remain part of the consolidated structure. ## Products & services • RPPA-based proteomics testing for oncology decision support • Protein signaling analysis for biopharmaceutical R&D • Laboratory services through Ignite Proteomics • Clinical revenue collection from patient and payer claims • Legacy outpatient rehabilitation and regenerative care operations - **Proteomics and oncology testing** (70%) — RPPA-based laboratory testing that quantifies protein signaling for cancer care and research. - **Biopharmaceutical research services** (20%) — Analytical services used by drug developers for biomarker and translational research. - **Clinical healthcare services** (10%) — Legacy outpatient and rehabilitation services billed to patients and third-party payers. - RPPA proteomics testing for oncology clinical treatment decisions - Protein signaling analytics for drug development and biomarker work - Laboratory services operated through Ignite Proteomics, LLC - Patient, insurance, and government reimbursement-based clinical services - Legacy outpatient rehabilitation and regenerative medicine services ## Customers The company sells primarily to oncology clinicians, hospitals, and biopharmaceutical companies that need protein-signaling data to guide treatment or development programs. It also has legacy healthcare customers, including patients and payers such as private insurers, government programs, and self-insured employers. Revenue remains very small, so customer concentration and the pace of commercial adoption are important to the business model. - **Oncology providers** (primary) — Clinicians and care centers that use Ignite's RPPA data to support cancer treatment decisions. - **Biopharmaceutical companies** (primary) — Drug developers that buy protein-signaling analysis for translational research and development. - **Patients and payers** (secondary) — Patients and reimbursement sources tied to legacy outpatient and rehabilitation services. - Oncology clinicians using proteomics data to support treatment choices - Biopharmaceutical companies buying biomarker and drug-development analytics - Patients receiving legacy outpatient and rehabilitation services - Private insurers and government programs reimbursing clinical services - Self-insured employers and other third-party payers ## Geography IMAC Holdings is headquartered in the United States and its disclosed business activity is overwhelmingly U.S.-based. The available filings do not provide a meaningful country revenue split, but the company’s laboratory, clinical, and payer relationships are tied to U.S. healthcare markets and reimbursement systems. That makes domestic funding access, labor availability, and payer mix more important than international expansion at this stage. - United States is the core operating and revenue market - Laboratory growth depends on U.S. financing and staffing conditions - Clinical collections come from U.S. private and government payers - No meaningful country-level revenue disclosure was provided - Geography is operationally concentrated rather than globally diversified ## Strategy Management is focused on funding the growth of its recently acquired laboratory and building out the Ignite Proteomics platform. The company also needs to recruit skilled laboratory and sales personnel while controlling overhead, because commercialization and operating leverage are still early-stage priorities. Preserving liquidity is central, as management has disclosed substantial doubt about going concern and a continuing need for external capital. - **Secure financing** (short-term) — The company needs external capital to fund laboratory expansion and ongoing operations. - **Commercialize Ignite Proteomics** (medium-term) — Revenue is minimal, so adoption of the RPPA platform is essential to create scale. - **Build operating capacity** (short-term) — Laboratory and sales staffing are needed to execute growth and manage overhead. - Raise additional capital to fund laboratory growth - Commercialize Ignite's RPPA proteomics platform - Expand oncology and biopharma customer adoption - Hire laboratory and sales staff to support scale-up - Control overhead while building operating capacity ## Risks The company faces going-concern and liquidity risk because it continues to burn cash and depends on external financing to fund operations. Execution risk is also high: the business must recruit specialized staff, scale a recently acquired laboratory, and convert a novel proteomics platform into recurring revenue. Legacy healthcare reimbursement, impairment charges, and legal costs add further volatility to reported results. - **Insufficient financing** [critical] — Management says additional capital is needed to fund future operations and laboratory growth. - **Going-concern uncertainty** [critical] — The company disclosed substantial doubt about its ability to continue as a going concern. - **Commercial adoption risk** [high] — Revenue is extremely small, so the RPPA platform must gain market acceptance to scale. - **Specialized labor shortages** [medium] — The company needs skilled laboratory and sales personnel at acceptable cost. - Going-concern risk due to recurring losses and capital needs - Financing risk if capital cannot be raised on acceptable terms - Commercialization risk for a novel proteomics platform - Labor and sales hiring risk in a specialized market - Impairment and legal costs can create earnings volatility ## Accounting The most important accounting issue is the company’s use of estimates in a very small and volatile revenue base, where changes in assumptions can materially affect results. Investors should also watch impairment charges, legal costs, and the treatment of discontinued operations, because these items can distort comparability from period to period. Cash collection from patients and third-party payers is another key area, since revenue and receivables depend on reimbursement timing and collectability. - **Revenue recognition and collectability** — Can affect reported revenue, receivables, and cash flow - **Impairment of property and equipment** — Can create sudden losses and reduce asset base - **Going-concern disclosures** — Affects investor assessment of liquidity and valuation - **Discontinued operations** — Can make trend analysis of core operations harder - Revenue is very small, so timing and collectability matter disproportionately - Accounts receivable collection from payers affects operating cash flow - Impairment charges can materially affect quarterly results - Legal fees and one-time Nasdaq listing costs add non-recurring volatility - Discontinued operations can obscure underlying continuing business performance --- *Last updated: 2026-04-28T20:15:42.893322+00:00*